Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 78

1.

Metastriate Ixodid Life Stages Protected from Predatory Ants in Texas.

Showler AT, Osbrink WLA, Dorsey BN, Caesar RM.

Environ Entomol. 2019 Sep 30;48(5):1063-1070. doi: 10.1093/ee/nvz097.

PMID:
31504376
2.

Inhibition of HBV replication by N-hydroxyisoquinolinedione and N-hydroxypyridinedione ribonuclease H inhibitors.

Edwards TC, Mani N, Dorsey B, Kakarla R, Rijnbrand R, Sofia MJ, Tavis JE.

Antiviral Res. 2019 Apr;164:70-80. doi: 10.1016/j.antiviral.2019.02.005. Epub 2019 Feb 12.

PMID:
30768944
3.

Structural organization of a Type III-A CRISPR effector subcomplex determined by X-ray crystallography and cryo-EM.

Dorsey BW, Huang L, Mondragón A.

Nucleic Acids Res. 2019 Apr 23;47(7):3765-3783. doi: 10.1093/nar/gkz079.

4.

Effects of Specific Electric Field Stimulation on the Release and Activity of Secreted Acid Phosphatases from Leishmania tarentolae and Implications for Therapy.

Dorsey BM, Cass CL, Cedeño DL, Vallejo R, Jones MA.

Pathogens. 2018 Sep 27;7(4). pii: E77. doi: 10.3390/pathogens7040077.

5.

Pleistocene diversification in an ancient lineage: a role for glacial cycles in the evolutionary history of Dioon Lindl. (Zamiaceae).

Dorsey BL, Gregory TJ, Sass C, Specht CD.

Am J Bot. 2018 Sep;105(9):1512-1530. doi: 10.1002/ajb2.1149. Epub 2018 Sep 7.

6.

Evidence That Speciation of Oxovanadium Complexes Does Not Solely Account for Inhibition of Leishmania Acid Phosphatases.

Dorsey BM, McLauchlan CC, Jones MA.

Front Chem. 2018 Apr 12;6:109. doi: 10.3389/fchem.2018.00109. eCollection 2018.

7.

Preclinical Profile of AB-423, an Inhibitor of Hepatitis B Virus Pregenomic RNA Encapsidation.

Mani N, Cole AG, Phelps JR, Ardzinski A, Cobarrubias KD, Cuconati A, Dorsey BD, Evangelista E, Fan K, Guo F, Guo H, Guo JT, Harasym TO, Kadhim S, Kultgen SG, Lee ACH, Li AHL, Long Q, Majeski SA, Mao R, McClintock KD, Reid SP, Rijnbrand R, Snead NM, Micolochick Steuer HM, Stever K, Tang S, Wang X, Zhao Q, Sofia MJ.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e00082-18. doi: 10.1128/AAC.00082-18. Print 2018 Jun.

8.

HBsAg mRNA degradation induced by a dihydroquinolizinone compound depends on the HBV posttranscriptional regulatory element.

Zhou T, Block T, Liu F, Kondratowicz AS, Sun L, Rawat S, Branson J, Guo F, Steuer HM, Liang H, Bailey L, Moore C, Wang X, Cuconatti A, Gao M, Lee ACH, Harasym T, Chiu T, Gotchev D, Dorsey B, Rijnbrand R, Sofia MJ.

Antiviral Res. 2018 Jan;149:191-201. doi: 10.1016/j.antiviral.2017.11.009. Epub 2017 Nov 10.

PMID:
29133129
9.

Combined inhibition of atypical PKC and histone deacetylase 1 is cooperative in basal cell carcinoma treatment.

Mirza AN, Fry MA, Urman NM, Atwood SX, Roffey J, Ott GR, Chen B, Lee A, Brown AS, Aasi SZ, Hollmig T, Ator MA, Dorsey BD, Ruggeri BR, Zificsak CA, Sirota M, Tang JY, Butte A, Epstein E, Sarin KY, Oro AE.

JCI Insight. 2017 Nov 2;2(21). pii: 97071. doi: 10.1172/jci.insight.97071.

10.

Protein catalyzed capture agents with tailored performance for in vitro and in vivo applications.

Coppock MB, Warner CR, Dorsey B, Orlicki JA, Sarkes DA, Lai BT, Pitram SM, Rohde RD, Malette J, Wilson JA, Kearney P, Fang KC, Law SM, Candelario SL, Farrow B, Finch AS, Agnew HD, Heath JR, Stratis-Cullum DN.

Biopolymers. 2017 Mar;108(2). doi: 10.1002/bip.22934.

11.

Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK).

Ott GR, Cheng M, Learn KS, Wagner J, Gingrich DE, Lisko JG, Curry M, Mesaros EF, Ghose AK, Quail MR, Wan W, Lu L, Dobrzanski P, Albom MS, Angeles TS, Wells-Knecht K, Huang Z, Aimone LD, Bruckheimer E, Anderson N, Friedman J, Fernandez SV, Ator MA, Ruggeri BA, Dorsey BD.

J Med Chem. 2016 Aug 25;59(16):7478-96. doi: 10.1021/acs.jmedchem.6b00487. Epub 2016 Aug 15.

PMID:
27527804
12.

Euphorbia plant latex is inhabited by diverse microbial communities.

Gunawardana M, Hyde ER, Lahmeyer S, Dorsey BL, La Val TP, Mullen M, Yoo J, Knight R, Baum MM.

Am J Bot. 2015 Dec;102(12):1966-77. doi: 10.3732/ajb.1500223. Epub 2015 Dec 11.

13.

An Additional Method for Analyzing the Reversible Inhibition of an 
Enzyme Using Acid Phosphatase as a Model.

Baumhardt JM, Dorsey BM, McLauchlan CC, Jones MA.

Curr Enzym Inhib. 2015 Aug;11(2):140-146. doi: 10.2174/1573408011666150605223952.

14.

Piperidine-3,4-diol and piperidine-3-ol derivatives of pyrrolo[2,1-f][1,2,4]triazine as inhibitors of anaplastic lymphoma kinase.

Mesaros EF, Angeles TS, Albom MS, Wagner JC, Aimone LD, Wan W, Lu L, Huang Z, Olsen M, Kordwitz E, Haltiwanger RC, Landis AJ, Cheng M, Ruggeri BA, Ator MA, Dorsey BD, Ott GR.

Bioorg Med Chem Lett. 2015 Mar 1;25(5):1047-52. doi: 10.1016/j.bmcl.2015.01.019. Epub 2015 Jan 17.

PMID:
25655723
15.

Design, synthesis, and biological evaluation of sulfonyl acrylonitriles as novel inhibitors of cancer metastasis and spread.

Shen Y, Zificsak CA, Shea JE, Lao X, Bollt O, Li X, Lisko JG, Theroff JP, Scaife CL, Ator MA, Ruggeri BA, Dorsey BD, Kuwada SK.

J Med Chem. 2015 Feb 12;58(3):1140-58. doi: 10.1021/jm501437v. Epub 2015 Jan 26.

PMID:
25581261
16.

Evolutionary bursts in Euphorbia (Euphorbiaceae) are linked with photosynthetic pathway.

Horn JW, Xi Z, Riina R, Peirson JA, Yang Y, Dorsey BL, Berry PE, Davis CC, Wurdack KJ.

Evolution. 2014 Dec;68(12):3485-504. doi: 10.1111/evo.12534. Epub 2014 Nov 20.

17.

Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review.

Mesaros EF, Ott GR, Dorsey BD.

Expert Opin Ther Pat. 2014 Apr;24(4):417-42. doi: 10.1517/13543776.2014.877890. Epub 2014 Jan 30. Review.

PMID:
24476492
18.

Recovery efficiencies for Burkholderia thailandensis from various aerosol sampling media.

Dabisch P, Bower K, Dorsey B, Wronka L.

Front Cell Infect Microbiol. 2012 Jun 11;2:78. doi: 10.3389/fcimb.2012.00078. eCollection 2012.

19.

A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779.

Dugan BJ, Gingrich DE, Mesaros EF, Milkiewicz KL, Curry MA, Zulli AL, Dobrzanski P, Serdikoff C, Jan M, Angeles TS, Albom MS, Mason JL, Aimone LD, Meyer SL, Huang Z, Wells-Knecht KJ, Ator MA, Ruggeri BA, Dorsey BD.

J Med Chem. 2012 Jun 14;55(11):5243-54. doi: 10.1021/jm300248q. Epub 2012 May 18.

PMID:
22594690
20.

Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase.

Gingrich DE, Lisko JG, Curry MA, Cheng M, Quail M, Lu L, Wan W, Albom MS, Angeles TS, Aimone LD, Haltiwanger RC, Wells-Knecht K, Ott GR, Ghose AK, Ator MA, Ruggeri B, Dorsey BD.

J Med Chem. 2012 May 24;55(10):4580-93. doi: 10.1021/jm201550q. Epub 2012 May 7.

PMID:
22564207
21.

Synthesis and biological evaluation of sulfonyl acrylonitriles as novel inhibitors to peritoneal carcinomatosis.

Zificsak CA, Shen Y, Lisko JG, Theroff JP, Lao X, Bollt O, Li X, Dorsey BD, Kuwada SK.

Bioorg Med Chem Lett. 2012 Mar 1;22(5):1850-3. doi: 10.1016/j.bmcl.2012.01.085. Epub 2012 Jan 30.

PMID:
22326395
22.

CEP-32496: a novel orally active BRAF(V600E) inhibitor with selective cellular and in vivo antitumor activity.

James J, Ruggeri B, Armstrong RC, Rowbottom MW, Jones-Bolin S, Gunawardane RN, Dobrzanski P, Gardner MF, Zhao H, Cramer MD, Hunter K, Nepomuceno RR, Cheng M, Gitnick D, Yazdanian M, Insko DE, Ator MA, Apuy JL, Faraoni R, Dorsey BD, Williams M, Bhagwat SS, Holladay MW.

Mol Cancer Ther. 2012 Apr;11(4):930-41. doi: 10.1158/1535-7163.MCT-11-0645. Epub 2012 Feb 7.

23.

Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery.

Ghose AK, Herbertz T, Hudkins RL, Dorsey BD, Mallamo JP.

ACS Chem Neurosci. 2012 Jan 18;3(1):50-68. Epub 2011 Nov 2.

24.

CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers.

Cheng M, Quail MR, Gingrich DE, Ott GR, Lu L, Wan W, Albom MS, Angeles TS, Aimone LD, Cristofani F, Machiorlatti R, Abele C, Ator MA, Dorsey BD, Inghirami G, Ruggeri BA.

Mol Cancer Ther. 2012 Mar;11(3):670-9. doi: 10.1158/1535-7163.MCT-11-0776. Epub 2011 Dec 27.

25.

Design, synthesis, and anaplastic lymphoma kinase (ALK) inhibitory activity for a novel series of 2,4,8,22-tetraazatetracyclo[14.3.1.1³,⁷.1⁹,¹³]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene macrocycles.

Breslin HJ, Lane BM, Ott GR, Ghose AK, Angeles TS, Albom MS, Cheng M, Wan W, Haltiwanger RC, Wells-Knecht KJ, Dorsey BD.

J Med Chem. 2012 Jan 12;55(1):449-64. doi: 10.1021/jm201333e. Epub 2011 Dec 15.

PMID:
22172029
26.

Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases.

Zificsak CA, Gingrich DE, Breslin HJ, Dunn DD, Milkiewicz KL, Theroff JP, Thieu TV, Underiner TL, Weinberg LR, Aimone LD, Albom MS, Mason JL, Saville L, Husten J, Angeles TS, Finn JP, Jan M, O'Kane TM, Dobrzanski P, Dorsey BD.

Bioorg Med Chem Lett. 2012 Jan 1;22(1):133-7. doi: 10.1016/j.bmcl.2011.11.049. Epub 2011 Nov 25.

PMID:
22169263
27.

Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.

Rowbottom MW, Faraoni R, Chao Q, Campbell BT, Lai AG, Setti E, Ezawa M, Sprankle KG, Abraham S, Tran L, Struss B, Gibney M, Armstrong RC, Gunawardane RN, Nepomuceno RR, Valenta I, Hua H, Gardner MF, Cramer MD, Gitnick D, Insko DE, Apuy JL, Jones-Bolin S, Ghose AK, Herbertz T, Ator MA, Dorsey BD, Ruggeri B, Williams M, Bhagwat S, James J, Holladay MW.

J Med Chem. 2012 Feb 9;55(3):1082-105. doi: 10.1021/jm2009925. Epub 2012 Jan 23.

PMID:
22168626
28.

Strategies to mitigate the bioactivation of 2-anilino-7-aryl-pyrrolo[2,1-f][1,2,4]triazines: identification of orally bioavailable, efficacious ALK inhibitors.

Mesaros EF, Thieu TV, Wells GJ, Zificsak CA, Wagner JC, Breslin HJ, Tripathy R, Diebold JL, McHugh RJ, Wohler AT, Quail MR, Wan W, Lu L, Huang Z, Albom MS, Angeles TS, Wells-Knecht KJ, Aimone LD, Cheng M, Ator MA, Ott GR, Dorsey BD.

J Med Chem. 2012 Jan 12;55(1):115-25. doi: 10.1021/jm2010767. Epub 2011 Dec 29.

PMID:
22141319
29.

Pyrazolone-based anaplastic lymphoma kinase (ALK) inhibitors: control of selectivity by a benzyloxy group.

Tripathy R, McHugh RJ, Ghose AK, Ott GR, Angeles TS, Albom MS, Huang Z, Aimone LD, Cheng M, Dorsey BD.

Bioorg Med Chem Lett. 2011 Dec 15;21(24):7261-4. doi: 10.1016/j.bmcl.2011.10.055. Epub 2011 Oct 20.

PMID:
22061645
30.

2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: modification of target structure to minimize reactive metabolite formation.

Weinberg LR, Albom MS, Angeles TS, Breslin HJ, Gingrich DE, Huang Z, Lisko JG, Mason JL, Milkiewicz KL, Thieu TV, Underiner TL, Wells GJ, Wells-Knecht KJ, Dorsey BD.

Bioorg Med Chem Lett. 2011 Dec 15;21(24):7325-30. doi: 10.1016/j.bmcl.2011.10.032. Epub 2011 Oct 14.

PMID:
22041060
31.

2,7-Disubstituted-pyrrolotriazine kinase inhibitors with an unusually high degree of reactive metabolite formation.

Wells-Knecht KJ, Ott GR, Cheng M, Wells GJ, Breslin HJ, Gingrich DE, Weinberg L, Mesaros EF, Huang Z, Yazdanian M, Ator MA, Aimone LD, Zeigler K, Dorsey BD.

Chem Res Toxicol. 2011 Nov 21;24(11):1994-2003. doi: 10.1021/tx200304r. Epub 2011 Nov 4.

PMID:
22023349
32.

Discovery of a novel class of non-ATP site DFG-out state p38 inhibitors utilizing computationally assisted virtual fragment-based drug design (vFBDD).

Moffett K, Konteatis Z, Nguyen D, Shetty R, Ludington J, Fujimoto T, Lee KJ, Chai X, Namboodiri H, Karpusas M, Dorsey B, Guarnieri F, Bukhtiyarova M, Springman E, Michelotti E.

Bioorg Med Chem Lett. 2011 Dec 1;21(23):7155-65. doi: 10.1016/j.bmcl.2011.09.078. Epub 2011 Sep 28.

PMID:
22014550
33.

Inhibitory effects of decavanadate on several enzymes and Leishmania tarentolae in vitro.

Turner TL, Nguyen VH, McLauchlan CC, Dymon Z, Dorsey BM, Hooker JD, Jones MA.

J Inorg Biochem. 2012 Mar;108:96-104. doi: 10.1016/j.jinorgbio.2011.09.009. Epub 2011 Sep 14.

PMID:
22005446
34.

Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group.

Milkiewicz KL, Aimone LD, Albom MS, Angeles TS, Chang H, Grobelny JV, Husten J, Losardo C, Miknyoczki S, Murthy S, Rolon-Steele D, Underiner TL, Weinberg LR, Worrell CS, Zeigler KS, Dorsey BD.

Bioorg Med Chem. 2011 Nov 1;19(21):6274-84. doi: 10.1016/j.bmc.2011.09.006. Epub 2011 Sep 13.

PMID:
21967808
35.

Effect of time from estrus to AI on pregnancy rates in estrous synchronized beef heifers.

Dorsey BR, Kasimanickam R, Whittier WD, Nebel RL, Wahlberg ML, Hall JB.

Anim Reprod Sci. 2011 Aug;127(1-2):1-6. doi: 10.1016/j.anireprosci.2011.07.014. Epub 2011 Jul 30.

PMID:
21911186
36.

Depletion of autoreactive plasma cells and treatment of lupus nephritis in mice using CEP-33779, a novel, orally active, selective inhibitor of JAK2.

Lu LD, Stump KL, Wallace NH, Dobrzanski P, Serdikoff C, Gingrich DE, Dugan BJ, Angeles TS, Albom MS, Mason JL, Ator MA, Dorsey BD, Ruggeri BA, Seavey MM.

J Immunol. 2011 Oct 1;187(7):3840-53. doi: 10.4049/jimmunol.1101228. Epub 2011 Aug 31.

37.

2,7-disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity.

Ott GR, Wells GJ, Thieu TV, Quail MR, Lisko JG, Mesaros EF, Gingrich DE, Ghose AK, Wan W, Lu L, Cheng M, Albom MS, Angeles TS, Huang Z, Aimone LD, Ator MA, Ruggeri BA, Dorsey BD.

J Med Chem. 2011 Sep 22;54(18):6328-41. doi: 10.1021/jm200758k. Epub 2011 Aug 22.

PMID:
21859094
38.

4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors.

Holladay MW, Campbell BT, Rowbottom MW, Chao Q, Sprankle KG, Lai AG, Abraham S, Setti E, Faraoni R, Tran L, Armstrong RC, Gunawardane RN, Gardner MF, Cramer MD, Gitnick D, Ator MA, Dorsey BD, Ruggeri BR, Williams M, Bhagwat SS, James J.

Bioorg Med Chem Lett. 2011 Sep 15;21(18):5342-6. doi: 10.1016/j.bmcl.2011.07.019. Epub 2011 Jul 14.

PMID:
21807507
39.

Discovery and process synthesis of novel 2,7-pyrrolo[2,1-f][1,2,4]triazines.

Thieu T, Sclafani JA, Levy DV, McLean A, Breslin HJ, Ott GR, Bakale RP, Dorsey BD.

Org Lett. 2011 Aug 19;13(16):4204-7. doi: 10.1021/ol2015237. Epub 2011 Jul 26.

PMID:
21790122
40.

Methanesulfonamido-cyclohexylamine derivatives of 2,4-diaminopyrimidine as potent ALK inhibitors.

Zificsak CA, Theroff JP, Aimone LD, Angeles TS, Albom MS, Cheng M, Mesaros EF, Ott GR, Quail MR, Underiner TL, Wan W, Dorsey BD.

Bioorg Med Chem Lett. 2011 Jul 1;21(13):3877-80. doi: 10.1016/j.bmcl.2011.05.040. Epub 2011 May 18.

PMID:
21632243
41.

A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis.

Stump KL, Lu LD, Dobrzanski P, Serdikoff C, Gingrich DE, Dugan BJ, Angeles TS, Albom MS, Ator MA, Dorsey BD, Ruggeri BA, Seavey MM.

Arthritis Res Ther. 2011 Apr 21;13(2):R68. doi: 10.1186/ar3329.

42.

P3 optimization of functional potency, in vivo efficacy and oral bioavailability in 3-aminopyrazinone thrombin inhibitors bearing non-charged groups at the P1 position.

Isaacs RC, Newton CL, Cutrona KJ, Mercer SP, Dorsey BD, McDonough CM, Cook JJ, Krueger JA, Lewis SD, Lucas BJ, Lyle EA, Lynch JJ, Miller-Stein C, Michener MT, Wallace AA, White RB, Wong BK.

Bioorg Med Chem Lett. 2011 Mar 1;21(5):1532-5. doi: 10.1016/j.bmcl.2010.12.108. Epub 2010 Dec 28.

PMID:
21295466
43.

2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines.

Zificsak CA, Theroff JP, Aimone LD, Albom MS, Angeles TS, Brown RA, Galinis D, Grobelny JV, Herbertz T, Husten J, Kocsis LS, LoSardo C, Miknyoczki SJ, Murthy S, Rolon-Steele D, Underiner TL, Wells-Knecht KJ, Worrell CS, Zeigler KS, Dorsey BD.

Bioorg Med Chem Lett. 2011 Jan 15;21(2):660-3. doi: 10.1016/j.bmcl.2010.12.013. Epub 2010 Dec 8.

PMID:
21190849
44.

Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity.

Ott GR, Tripathy R, Cheng M, McHugh R, Anzalone AV, Underiner TL, Curry MA, Quail MR, Lu L, Wan W, Angeles TS, Albom MS, Aimone LD, Ator MA, Ruggeri BA, Dorsey BD.

ACS Med Chem Lett. 2010 Sep 1;1(9):493-8. doi: 10.1021/ml100158s. eCollection 2010 Dec 9.

45.

Synthesis and pharmacological evaluation of N-(3-(1H-indol-4-yl)-5-(2-methoxyisonicotinoyl)phenyl)methanesulfonamide (LP-261), a potent antimitotic agent.

Shetty RS, Lee Y, Liu B, Husain A, Joseph RW, Lu Y, Nelson D, Mihelcic J, Chao W, Moffett KK, Schumacher A, Flubacher D, Stojanovic A, Bukhtiyarova M, Williams K, Lee KJ, Ochman AR, Saporito MS, Moore WR, Flynn GA, Dorsey BD, Springman EB, Fujimoto T, Kelly MJ.

J Med Chem. 2011 Jan 13;54(1):179-200. doi: 10.1021/jm100659v. Epub 2010 Dec 2.

PMID:
21126027
46.

Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors.

Weinberg LR, Albom MS, Angeles TS, Husten J, Lisko JG, McHugh RJ, Milkiewicz KL, Murthy S, Ott GR, Theroff JP, Tripathy R, Underiner TL, Zificsak CA, Dorsey BD.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):164-7. doi: 10.1016/j.bmcl.2010.11.045. Epub 2010 Nov 11.

PMID:
21123062
47.

Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models.

Mesaros EF, Burke JP, Parrish JD, Dugan BJ, Anzalone AV, Angeles TS, Albom MS, Aimone LD, Quail MR, Wan W, Lu L, Huang Z, Ator MA, Ruggeri BA, Cheng M, Ott GR, Dorsey BD.

Bioorg Med Chem Lett. 2011 Jan 1;21(1):463-6. doi: 10.1016/j.bmcl.2010.10.115. Epub 2010 Oct 27. Erratum in: Bioorg Med Chem Lett. 2011 Mar 15;21(6):1900.

PMID:
21074994
48.

Discovery and SAR of a series of 4,6-diamino-1,3,5-triazin-2-ol as novel non-nucleoside reverse transcriptase inhibitors of HIV-1.

Liu B, Lee Y, Zou J, Petrassi HM, Joseph RW, Chao W, Michelotti EL, Bukhtiyarova M, Springman EB, Dorsey BD.

Bioorg Med Chem Lett. 2010 Nov 15;20(22):6592-6. doi: 10.1016/j.bmcl.2010.09.034. Epub 2010 Sep 21.

PMID:
20888224
49.

Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase.

Milkiewicz KL, Weinberg LR, Albom MS, Angeles TS, Cheng M, Ghose AK, Roemmele RC, Theroff JP, Underiner TL, Zificsak CA, Dorsey BD.

Bioorg Med Chem. 2010 Jun 15;18(12):4351-62. doi: 10.1016/j.bmc.2010.04.087. Epub 2010 Apr 29.

PMID:
20483621
50.

Structure-based design of substituted biphenyl ethylene ethers as ligands binding in the hydrophobic pocket of gp41 and blocking the helical bundle formation.

Liu B, Joseph RW, Dorsey BD, Schiksnis RA, Northrop K, Bukhtiyarova M, Springman EB.

Bioorg Med Chem Lett. 2009 Oct 1;19(19):5693-7. doi: 10.1016/j.bmcl.2009.08.018. Epub 2009 Aug 8.

PMID:
19699090

Supplemental Content

Loading ...
Support Center